{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:50:05Z","timestamp":1769075405931,"version":"3.49.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>To develop and internally validate a novel predictive model for <jats:italic>SDHB<\/jats:italic> mutations in pheochromocytomas and retroperitoneal paragangliomas (PPGLs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical data of patients with PPGLs who presented to Peking Union Medical College Hospital from 2013 to 2022 and underwent genetic testing were retrospectively collected. Variables were screened by backward stepwise and clinical significance and were used to construct multivariable logistic models in 50 newly generated datasets after the multiple imputation. Bootstrapping was used for internal validation. A corresponding nomogram was generated based on the model. Sensitivity analyses were also performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 556 patients with PPGLs were included, of which 99 had a germline <jats:italic>SDHB<\/jats:italic> mutation. The prediction model revealed that younger age of onset [Odds ratio (OR): 0.93, 95% CI: 0.91-0.95], synchronous metastasis (OR: 6.43, 95% CI: 2.62-15.80), multiple lesion (OR: 0.22, 95% CI: 0.09-0.54), retroperitoneal origin (OR: 5.72, 95% CI: 3.13-10.47), negative 131I-meta-iodobenzylguanidine (MIBG) (OR: 0.34, 95% CI: 0.15-0.73), positive octreotide scintigraphy (OR: 3.24, 95% CI: 1.25-8.43), elevated 24h urinary dopamine (DA) (OR: 1.72, 95% CI: 0.93-3.17), NE secretory type (OR: 2.83, 95% CI: 1.22- 6.59), normal secretory function (OR: 3.04, 95% CI: 1.04-8.85) and larger tumor size (OR: 1.09, 95% CI: 0.99-1.20) were predictors of <jats:italic>SDHB<\/jats:italic> mutations in PPGLs, and showed good and stable predictive performance with a mean area under the ROC curve (AUC) of 0.865 and coefficient of variation of 2.2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provided a novel and useful tool for predicting <jats:italic>SDHB<\/jats:italic> mutations by integrating easily obtained clinical data. It may help clinicians select suitable genetic testing methods and make appropriate clinical decisions for these high-risk patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1285631","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:50:25Z","timestamp":1703134225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and internal validation of a novel predictive model for SDHB mutations in pheochromocytomas and retroperitoneal paragangliomas"],"prefix":"10.3389","volume":"14","author":[{"given":"Yue","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingding","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anli","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1093\/hmg\/ddaa201","article-title":"Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine","volume":"29","author":"Casey","year":"2020","journal-title":"Hum Mol Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.05.025","article-title":"Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery","volume":"163","author":"Nockel","year":"2018","journal-title":"Surg Jan"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.currproblcancer.2014.01.001","article-title":"Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment","volume":"38","author":"Martucci","year":"2014","journal-title":"Curr Probl Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106324","article-title":"Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis","volume":"57","author":"Lee","year":"2020","journal-title":"J Med Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/erc-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03138-5","article-title":"Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents","volume":"146","author":"Jochmanova","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2012-101192","article-title":"Risk of Malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis","volume":"49","author":"van Hulsteijn","year":"2012","journal-title":"J Med Genet Dec"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4158\/ep15725.Or","article-title":"Characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr practice: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.574662","article-title":"Genetic and clinical profiles of pheochromocytoma and paraganglioma: A single center study","volume":"11","author":"Ma","year":"2020","journal-title":"Front Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-018-0579-4","article-title":"Continued tumor reduction of metastatic pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy","volume":"38","author":"Jawed","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1179554918763367","article-title":"Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature","volume":"12","author":"Tena","year":"2018","journal-title":"Clin Med Insights Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907843106","article-title":"Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues","volume":"106","author":"Ziegler","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701441848","article-title":"Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours","volume":"46","author":"Van Essen","year":"2007","journal-title":"Acta Oncol (Stockholm Sweden)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for Malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol"},{"key":"B22","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med: Off Publ Soc Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1311637","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)","volume":"44","author":"Zovato","year":"2012","journal-title":"Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones metabol"},{"key":"B24","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol imaging: Off Publ Ital Assoc Nucl Med (AIMN) [and] Int Assoc Radiopharmacol (IAR) [and] Section So."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with (177)Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14106","article-title":"\u2018Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis\u2019","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac657","article-title":"Efficacy and safety of tyrosine kinase inhibitors in patients with metastatic pheochromocytomas\/paragangliomas","volume":"108","author":"Zhou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/erc-21-0355","article-title":"Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures","volume":"29","author":"Wang","year":"2022","journal-title":"Endocrine-Related Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cge.13055","article-title":"The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers","volume":"93","author":"Rijken","year":"2018","journal-title":"Clin Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/cen.12074","article-title":"Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma","volume":"78","author":"Jafri","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105427","article-title":"Bayesian approach to determining penetrance of pathogenic SDH variants","volume":"55","author":"Benn","year":"2018","journal-title":"J Med Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2015.08.006","article-title":"Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment","volume":"25","author":"Kiernan","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1530\/erc-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.05.001","article-title":"A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score","volume":"164","author":"Cho","year":"2018","journal-title":"Surg Sep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.kint.2020.07.035","article-title":"A practical guide to multiple imputation of missing data in nephrology","volume":"99","author":"Blazek","year":"2021","journal-title":"Kidney Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/09622802211047346","article-title":"Multiple imputation with missing data indicators","volume":"30","author":"Beesley","year":"2021","journal-title":"Stat Methods Med Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.014","article-title":"Review: a gentle introduction to imputation of missing values","volume":"59","author":"Donders","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/m14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Internal Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J Clin Epidemiol Aug"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/03610918.2017.1303726","article-title":"An evaluation of the bootstrap for model validation in mixture models","volume":"47","author":"Jaki","year":"2018","journal-title":"Commun Stat: Simulation Computation"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3853","article-title":"The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3)","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.09.015","article-title":"Differences in clinical manifestations and tumor features between metastatic pheochromocytoma\/paraganglioma patients with and without germline SDHB mutation","volume":"27","author":"Cui","year":"2021","journal-title":"Endocr Pract"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11419-1","article-title":"Clinical predictors of pseudohypoxia-type pheochromocytomas","volume":"29","author":"Baechle","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1677\/erc.1.00838","article-title":"Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocrine-Related Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0904","article-title":"Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma","volume":"59","author":"Eisenhofer","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01984-3","article-title":"Development and validation of a novel nomogram predicting pseudohypoxia type pheochromocytomas and paragangliomas","volume":"46","author":"Wang","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of Malignant pheochromocytoma and paraganglioma (MAPP-prono study): A european network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1285631\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:50:29Z","timestamp":1703134229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1285631\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":54,"alternative-id":["10.3389\/fendo.2023.1285631"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1285631","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"article-number":"1285631"}}